Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation

Sadat City University

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Irritable Bowel Syndrome With Diarrhea

Treatments

Drug: Rifaximin 550Mg Tab

Drug: Nitazoxanide 500Mg Oral Tablet

Study type

Interventional

Funder types

Other

Identifiers

NCT05453916

202207MH1

Details and patient eligibility

About

This study aim to compare the efficacy of nitazoxanide in 2-week course of treatment with rifaximin in treating diarrhea associated with IBS. We also aim to study its effect over 10 weeks after treatment to evaluate its efficacy in eradicating symptoms of IBS in the long run.

Enrollment

84 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients 18 years of age or older.
Patients suffering from diarrhea-predominant IBS according to Rome III criteria.
Active symptoms for at least 2 weeks
Abdominal Pain Intensity: weekly average of worst daily (in past 24 hours) abdominal pain score of > 3.0 on a 0-to-10-point scale and Stool Consistency: at least one stool with a consistency of Type 6 or Type 7 Bristol stool score (BSS) on at least 2 days per week
Report no restriction whatsoever on their diet.

Exclusion criteria

Presence of liver disease, malignancy, severe malabsorption, bedridden, endocrinological disorders, or severe chronic obstructive pulmonary disease.
Patients who have undergone abdominal surgeries except for appendectomy and/or cholecystectomy and/or hysterectomy.
Patients who consumed any medications that may affect bowel function within the last 2 weeks such as antibiotics, probiotics, prebiotics, antispasmodics, antidiarrheals, narcotics, or any other medication that may alter bowel function
Patients on antidepressants or antipsychotics starting within the last six weeks before eligibility check.